α-Chymotrypsin-catalyzed degradation of desmopressin (dDAVP): Influence of pH, concentration and various cyclodextrins

International Journal of Pharmaceutics

Volumn 178, Issue 2, 1999, Pages 223-229

  Fredholt, Karin ^a   Østergaard, Jesper ^a   Savolainen, Jouko ^b   Friis, Gitte Juel ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Chymotrypsin; Cyclodextrin; Desmopressin (dDAVP); Enzyme kinetics; Hydrolysis; Stability

Indexed keywords

CHYMOTRYPSIN A; CYCLODEXTRIN; DESMOPRESSIN; PHENYLALANINE;

ARTICLE; CHEMICAL REACTION KINETICS; COMPLEX FORMATION; DOSE RESPONSE; DRUG DEGRADATION; DRUG STABILITY; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; PH; PRIORITY JOURNAL; REACTION ANALYSIS;

CHYMOTRYPSIN; CYCLODEXTRINS; DEAMINO ARGININE VASOPRESSIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; PHENYLALANINE;

EID: 0033057186     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00377-9     Document Type: Article

References (19)

1. Brewster M.E., Hora M.S., Simpkins J.W., Bodor N. Use of 2-hydroxypropyl-β-cyclodextrin as a solubilizing and stabilizing excipient for protein drugs. Pharm. Res. 8:1991;792-795.
2. Haeberlin B., Gengenbacher T., Meinzer A., Fricker G. Cyclodextrins - useful excipients for oral peptide administration? Int. J. Pharm. 137:1996;103-110.
3. Harris A.S., Nilsson I.M., Wagner Z.G., Alkner U. Intranasal administration of peptides: nasal deposition, biological response, and absorption of desmopressin. J. Pharm. Sci. 75:1986;1085-1088.
4. Hess G.P. Chymotrypsin - chemical properties and catalysis. Boyer P.D. The Enzymes. III:1971;213-248 Academic Press, New York.
5. Irie T., Wakamatsu K., Arima H., Aritomi H., Uekama K. Enhancing effects of cyclodextrins on nasal absorption of insulin in rats. Int. J. Pharm. 84:1992;129-139.
6. Kahns A.H., Buur A., Bundgaard H. Prodrugs of peptides. 18. Synthesis and evaluation of various esters of desmopressin (dDAVP). Pharm. Res. 10:1993;68-74.
7. Kihlberg J., Åhman J., Walse B., Drakenberg T., Nilsson A., Söderberg-Ahlm C., Bengtsson B., Olsson H. Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8-D-arginine]-vasopressin. J. Med. Chem. 38:1995;161-169.
8. Köhler M., Harris A. Pharmacokinetics and haematological effects of desmopressin. Eur. J. Clin. Pharmacol. 35:1988;281-285.
9. Lundin S., Artursson P. Absorption of a vasopressin analogue, 1-deamino-8-D-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell-line, CaCO-2. Int. J. Pharm. 64:1990;181-186.
10. 8]-vasopressin (dDAVP) in pancreatic juice and intestinal mucosa homogenate. Pharmacol. Toxicol. 65:1989;92-95.
11. Lundin S., Pantzar N., Broeders A., Ohlin M., Weström B.R. Differences in transport rate of oxytocin and vasopressin analogues across proximal and distal isolated segments of the small intestine of the rat. Pharm. Res. 8:1991;1274-1280.
12. Matsubara K., Ando Y., Irie T., Uekama K. Protection afforded by maltosyl-β-cyclodextrin against α-chymotrypsin-catalyzed hydrolysis of a luteinizing hormone-releasing hormone agonist, buserelin acetate. Pharm. Res. 14:1997;1401-1405.
13. Matsuyama K., El-Gizawy S., Perrin J.H. Thermodynamic binding of aromatic amino acids to α-, β- and γ-cyclodextrins. Drug Dev. Ind. Pharm. 13:1987;2687-2691.
14. Morimoto K., Yamaguchi H., Iwakura Y., Miyazaki M., Nakatani E., Iwamoto T., Ohashi Y., Nakai Y. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Pharm. Res. 8:1991;1175-1179.
15. Saffran M., Bedra C., Kumar G.S., Neckers D.C. Vasopressin: a model for the study of effects of additives on the oral and rectal administration of peptide drugs. J. Pharm. Sci. 77:1988;33-38.
16. Stella V.J., Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14:1997;556-567.
17. Szejtli J. Cyclodextrins in drug formulations: Part II. Pharm. Technol. Int. 3:1991;16-24.
18. Vilhardt H. Basic pharmacology of desmopressin. A review. Drug Invest. 2:1990;2-8.
19. Vilhardt H., Lundin S. Biological effect and plasma concentrations of DDAVP after intranasal and peroral administration to humans. Gen. Pharmacol. 17:1986;481-483.